943439-52-9Relevant academic research and scientific papers
Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity
Qin, Zhihui,Kastrati, Irida,Chandrasena, R. Esala P.,Liu, Hong,Yao, Ping,Petukhov, Pavel A.,Bolton, Judy L.,Thatcher, Gregory R. J.
, p. 2682 - 2692 (2007)
The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clinical use. Most SERMs are polyaromatic phenols susceptible to oxidative metabolism to quinoids, which are proposed to
COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
-
Page/Page column 96-97; 101-102, (2018/09/12)
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as tocompositions and ophthalmic devices comprising such compounds.
HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
-
Page/Page column 97; 98; 101, (2018/09/21)
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE
-
Paragraph 00500, (2018/08/20)
The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
